Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | PREP | P48147 | 3/20 | 0.49 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.47 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.47 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15970479 | 1.00 | HCRTR1 (0.59) | HCRTR1ALDH1A1OPRK1POLBMAPT | |
| SCHEMBL15743774 | 1.00 | HCRTR1 (0.59) | HCRTR1ALDH1A1OPRK1POLBMAPT | |
| SCHEMBL15743766 | 0.88 | HCRTR1 (0.70) | HCRTR1ALDH1A1OPRK1MAPTKMT2A | |
| SCHEMBL13099535 | 0.88 | HCRTR1 (0.70) | HCRTR1ALDH1A1OPRK1MAPTKMT2A | |
| SCHEMBL13099643 | 0.85 | ALDH1A1 (0.61) | HCRTR1ALDH1A1OPRK1PREP | |
| SCHEMBL13108601 | 0.85 | ALDH1A1 (0.61) | HCRTR1ALDH1A1OPRK1PREP | |
| SCHEMBL13099525 | 0.84 | OPRK1 (0.57) | HCRTR1ALDH1A1OPRK1POLBKMT2A | |
| SCHEMBL15743764 | 0.84 | OPRK1 (0.57) | HCRTR1ALDH1A1OPRK1POLBKMT2A | |
| SCHEMBL13099519 | 0.83 | HCRTR1 (0.62) | HCRTR1ALDH1A1OPRK1POLBKMT2A | |
| SCHEMBL13108463 | 0.83 | HCRTR1 (0.62) | HCRTR1ALDH1A1OPRK1POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735391-B2 | Synthesis of functionalized octahydro-isoquinolin-1-one-8-carboxamides, octahydro-isoquinolin-1-one-8-carboxylic esters and analogs, and therapeutic methods | UNIVERSITY OF KANSAS (US) | 2014-05-27 | — | — | US | disclosed |
| US-20100256142-A1 | SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS | UNIVERSITY OF NORTH CAROLINA | 2010-10-07 | — | — | US | disclosed |
| US-20100256142-A1 | SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS | UNIVERSITY OF NORTH CAROLINA | 2010-10-07 | — | — | US | disclosed |
| WO-2010037050-A2 | SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS | UNIVERSITY OF KANSAS (US) | 2010-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256142-A1 | SYNTHESIS OF FUNCTIONALIZED OCTAHYDRO-ISOQUINOLIN-1-ONE-8- CARBOXAMIDES, OCTAHYDRO-ISOQUINOLIN-1-ONE-8-CARBOXYLIC ESTERS AND ANALOGS, AND THERAPEUTIC METHODS | OPRM1, OPRK1, OPRL1 | HCRTR1 14/4885ALDH1A1 131/4885OPRK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.